In The Lancet Oncology, Josep Tabernero and colleagues 1 report the final analysis of the JACOB trial, which tested the efficacy and safety of pertuzumab (a monoclonal antibody targeting HER2 receptors) combined with
trastuzumab and chemotherapy in previously untreated patients with HER2-positive metastatic gastric or gastrooesophageal junction cancer. JACOB was the first trial to investigate a dual HER2 blockade in metastatic gastric
cancer; unfortunately, no significant improvement in overall survival was observed in the group treated with the dual-HER2 targeted combination.
